NovaBay Pharmaceuticals, Inc. (NBY)
USD 0.49
(-9.24%)
USD 0.49
(-9.24%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 7.89 Million USD | 1.47% |
| 2022 | 7.78 Million USD | 37.84% |
| 2021 | 5.64 Million USD | -5.35% |
| 2020 | 5.96 Million USD | 22.69% |
| 2019 | 4.86 Million USD | -55.83% |
| 2018 | 11 Million USD | -28.75% |
| 2017 | 15.44 Million USD | 63.74% |
| 2016 | 9.43 Million USD | 202.34% |
| 2015 | 3.12 Million USD | 449.3% |
| 2014 | 568 Thousand USD | -82.87% |
| 2013 | 3.31 Million USD | -52.23% |
| 2012 | 6.93 Million USD | -37.03% |
| 2011 | 11.01 Million USD | 12.97% |
| 2010 | 9.75 Million USD | -37.81% |
| 2009 | 15.68 Million USD | 133.32% |
| 2008 | 6.72 Million USD | 13.68% |
| 2007 | 5.91 Million USD | 285.71% |
| 2006 | 1.53 Million USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.79 Million USD | -1.16% |
| 2024 Q2 | 1.59 Million USD | -11.26% |
| 2023 Q1 | 1.93 Million USD | 10.31% |
| 2023 FY | 7.89 Million USD | 1.47% |
| 2023 Q2 | 2.3 Million USD | 19.11% |
| 2023 Q3 | 1.83 Million USD | -20.29% |
| 2023 Q4 | 1.81 Million USD | -1.25% |
| 2022 Q4 | 1.75 Million USD | -26.11% |
| 2022 Q1 | 1.51 Million USD | 6.24% |
| 2022 FY | 7.78 Million USD | 37.84% |
| 2022 Q2 | 1.55 Million USD | 2.24% |
| 2022 Q3 | 2.37 Million USD | 53.23% |
| 2021 Q4 | 1.42 Million USD | 5.94% |
| 2021 FY | 5.64 Million USD | -5.35% |
| 2021 Q1 | 1.35 Million USD | 25.77% |
| 2021 Q2 | 1.51 Million USD | 12.35% |
| 2021 Q3 | 1.34 Million USD | -11.32% |
| 2020 Q4 | 1.07 Million USD | -34.21% |
| 2020 Q1 | 1.31 Million USD | 18.0% |
| 2020 Q2 | 1.94 Million USD | 48.28% |
| 2020 FY | 5.96 Million USD | 22.69% |
| 2020 Q3 | 1.63 Million USD | -15.95% |
| 2019 Q2 | 1.38 Million USD | 20.52% |
| 2019 Q4 | 1.11 Million USD | -8.48% |
| 2019 FY | 4.86 Million USD | -55.83% |
| 2019 Q1 | 1.15 Million USD | -63.88% |
| 2019 Q3 | 1.21 Million USD | -12.41% |
| 2018 Q2 | 2.31 Million USD | -14.13% |
| 2018 FY | 11 Million USD | -28.75% |
| 2018 Q3 | 2.81 Million USD | 21.38% |
| 2018 Q4 | 3.18 Million USD | 13.31% |
| 2018 Q1 | 2.69 Million USD | -49.5% |
| 2017 Q3 | 3.57 Million USD | 4.26% |
| 2017 Q2 | 3.42 Million USD | 9.99% |
| 2017 Q1 | 3.11 Million USD | -4.77% |
| 2017 FY | 15.44 Million USD | 63.74% |
| 2017 Q4 | 5.33 Million USD | 49.55% |
| 2016 Q1 | 1.1 Million USD | 6.13% |
| 2016 Q4 | 3.26 Million USD | 13.82% |
| 2016 FY | 9.43 Million USD | 202.34% |
| 2016 Q3 | 2.87 Million USD | 31.5% |
| 2016 Q2 | 2.18 Million USD | 97.11% |
| 2015 Q2 | 755 Thousand USD | 93.59% |
| 2015 Q4 | 1.04 Million USD | 12.14% |
| 2015 Q3 | 931 Thousand USD | 23.31% |
| 2015 FY | 3.12 Million USD | 449.3% |
| 2015 Q1 | 390 Thousand USD | 101.03% |
| 2014 Q4 | 194 Thousand USD | 76.36% |
| 2014 Q1 | 158 Thousand USD | -63.26% |
| 2014 FY | 568 Thousand USD | -82.87% |
| 2014 Q2 | 105 Thousand USD | -33.54% |
| 2014 Q3 | 110 Thousand USD | 4.76% |
| 2013 Q4 | 430 Thousand USD | -59.28% |
| 2013 Q2 | 832 Thousand USD | -16.63% |
| 2013 Q3 | 1.05 Million USD | 26.92% |
| 2013 FY | 3.31 Million USD | -52.23% |
| 2013 Q1 | 998 Thousand USD | 198.42% |
| 2012 Q4 | -1.01 Million USD | -189.89% |
| 2012 FY | 6.93 Million USD | -37.03% |
| 2012 Q1 | 1.32 Million USD | 7.32% |
| 2012 Q2 | 871 Thousand USD | -34.02% |
| 2012 Q3 | 1.12 Million USD | 29.51% |
| 2011 Q4 | 1.23 Million USD | -55.63% |
| 2011 Q2 | 4.52 Million USD | 81.81% |
| 2011 Q1 | 2.49 Million USD | -17.98% |
| 2011 FY | 11.01 Million USD | 12.97% |
| 2011 Q3 | 2.77 Million USD | -38.77% |
| 2010 Q3 | 2.08 Million USD | -18.13% |
| 2010 Q4 | 3.03 Million USD | 45.54% |
| 2010 Q2 | 2.54 Million USD | 22.26% |
| 2010 Q1 | 2.08 Million USD | -72.18% |
| 2010 FY | 9.75 Million USD | -37.81% |
| 2009 Q3 | 3.22 Million USD | 36.78% |
| 2009 Q2 | 2.35 Million USD | -9.73% |
| 2009 Q1 | 2.61 Million USD | 18.9% |
| 2009 FY | 15.68 Million USD | 133.32% |
| 2009 Q4 | 7.49 Million USD | 132.38% |
| 2008 Q1 | 1.49 Million USD | -1.91% |
| 2008 Q4 | 2.19 Million USD | 37.94% |
| 2008 Q3 | 1.59 Million USD | 10.4% |
| 2008 FY | 6.72 Million USD | 13.68% |
| 2008 Q2 | 1.44 Million USD | -3.35% |
| 2007 Q2 | 1.46 Million USD | -1.21% |
| 2007 Q1 | 1.48 Million USD | 11.92% |
| 2007 Q3 | 1.44 Million USD | -1.43% |
| 2007 Q4 | 1.52 Million USD | 5.33% |
| 2007 FY | 5.91 Million USD | 285.71% |
| 2006 Q3 | 208 Thousand USD | 0.0% |
| 2006 FY | 1.53 Million USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q4 | 1.32 Million USD | 537.02% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 160 Thousand USD | -4834.375% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 3258.0% |
| Armata Pharmaceuticals, Inc. | -29.24 Million USD | 127.0% |
| Actinium Pharmaceuticals, Inc. | -709 Thousand USD | 1213.54% |
| Azitra, Inc. | 260.45 Thousand USD | -2931.28% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | -962.584% |
| Chromocell Therapeutics Corporation | -2.57 Million USD | 406.077% |
| Calidi Biotherapeutics, Inc. | -1.25 Million USD | 728.583% |
| CEL-SCI Corporation | -3.95 Million USD | 299.453% |
| iBio, Inc. | -1.02 Million USD | 870.244% |
| Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 4.581% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | -13.39 Million USD | 158.949% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 6718.048% |
| NanoViricides, Inc. | -759.01 Thousand USD | 1140.165% |
| Oragenics, Inc. | -15.45 Million USD | 151.091% |
| BiomX Inc. | -1.22 Million USD | 742.915% |
| BiomX Inc. | -1.22 Million USD | 742.915% |
| Protalix BioTherapeutics, Inc. | 42.51 Million USD | 81.429% |
| Palatin Technologies, Inc. | 4.39 Million USD | -79.74% |
| Scorpius Holdings, Inc. | -2.21 Million USD | 456.206% |